ALC-2205

ALC-2205 is a generic drug candidate currently under development by **Korea Arlico Pharm**, a South Korean pharmaceutical company. The agent is specifically targeted for the treatment of disorders within the **digestive system**. As a generic formulation, ALC-2205 is designed to be bioequivalent to an existing reference listed drug, aiming to provide a cost-effective therapeutic alternative upon regulatory approval and market launch. While the specific active pharmaceutical ingredient (API) has not been publicly disclosed in high-level pipeline summaries, the project represents a key component of Korea Arlico Pharm's strategy to expand its presence in the gastrointestinal therapeutic market.